Stopping adalimumab treatment for children with arthritis-related eye inflammation
Official title: Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial
Funded at University of California, San Francisco · NIH-10626013 · Data updated 2026-11-12
This study is looking at what happens when kids with juvenile idiopathic arthritis stop taking adalimumab, a medicine for eye inflammation, to see if they can safely go off it without their symptoms coming back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 1, 2019 |
| Project end | April 30, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,229,055 |
| NIH project number | 5UG1EY029658-05 |
| Project ID | NIH-10626013 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with juvenile idiopathic arthritis who are currently experiencing controlled uveitis.
✕Less likely to help
Patients who are not currently experiencing controlled uveitis or those who have not been treated with adalimumab may not benefit from this research.
What this research studies
This research investigates the effects of stopping adalimumab, a medication used to treat eye inflammation associated with juvenile idiopathic arthritis (JIA), in children whose condition is currently under control. The study will involve multiple centers and will randomly assign participants to either continue or stop the medication, while monitoring for any recurrence of inflammation. By comparing the rates and timing of any flare-ups, the research aims to establish guidelines for safely discontinuing treatment. This could help reduce the financial burden and risks associated with long-term medication use.
Why it matters
Potential benefit: If successful, this research could provide clearer guidelines for safely stopping adalimumab, potentially reducing treatment costs and minimizing the risk of side effects for patients.
How similar studies have gone: Previous research has shown that stopping and restarting anti-TNF-α therapy can affect responsiveness, indicating that this area of study is both relevant and necessary.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Acharya, Nisha — University of California, San Francisco
- Study coordinator: Acharya, Nisha
Related research
Other NIH-funded projects on the same topics.
-
Predicting eye inflammation in children with juvenile arthritis
This study is looking to help kids with juvenile idiopathic arthritis by finding better ways to spot and treat uveitis, an eye condition they might get, by checking their tears and genes to see who might be at risk.
-
Deciphering What Drives Juvenile Idiopathic Arthritis in African American Children
This project looks at why African American children with juvenile idiopathic arthritis have more joint damage, using clinical data and genetic information to find factors that may explain the differences.
-
Understanding how T cells make IFN-γ and IL-17 in kids with juvenile arthritis
A doctor-scientist at Vanderbilt is studying why certain immune cells in children with juvenile idiopathic arthritis produce inflammatory signals, with the goal of improving diagnosis and treatment.
-
Lung disease linked to systemic juvenile idiopathic arthritis in children
This project looks at how ongoing immune activation and some arthritis medicines may cause lung inflammation and breathing problems in children with systemic juvenile idiopathic arthritis (SJIA).
-
Linking JIA Registry with Claims Data to Improve Understanding of Juvenile Arthritis
A study will connect the CARRA JIA patient registry with a large national claims database to see how well registry data match real-world care and outcomes for children with juvenile idiopathic arthritis.
-
Investigating the role of viruses and gut bacteria in arthritis flares in children
This study is looking at how certain viruses and bacteria in the gut might affect flare-ups of juvenile idiopathic arthritis in kids, hoping to find clues that could help manage these painful episodes better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.